Some traders seem unsettled by a bit of downside volatility after not experiencing much of it of late.
AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.
Are the technical and quantitative approaches on the same page?
Time to review the charts and indicators.
GBT is dedicated to discovering, developing, and commercializing ways to treat blood disorders.
Let's review the charts and indicators of this Dublin-based biopharmaceutical.
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.
Shares of the pharma company have broken out on our Point and Figure chart.
Our technical outlook and strategy for the San Diego-based biotech.